Top-Rated StocksTop-RatedNASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $150.56 -3.76 (-2.44%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$150.69 +0.13 (+0.09%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Palvella Therapeutics Stock (NASDAQ:PVLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$149.20▼$154.7250-Day Range$124.15▼$157.7752-Week Range$56.22▼$161.38Volume646,460 shsAverage Volume186,695 shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/APrice Target$209.14Consensus RatingBuy Company Overview Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure. Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system. The company has also evaluated QTORIN-based rapamycin formulations in other rare skin disorders, including pachyonychia congenita, a painful inherited disease affecting the nails, skin and feet. Based in Wayne, Pennsylvania, Palvella is advancing its pipeline through clinical development and regulatory activities in the United States. The company’s programs are intended to address conditions for which treatment options remain limited, and its strategy is centered on developing targeted therapies for underserved rare-disease populations.AI Generated. May Contain Errors. Read More Palvella Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 607th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingPalvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalvella Therapeutics has a consensus price target of $209.14, representing about 38.9% upside from its current price of $150.56.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palvella Therapeutics are expected to decrease in the coming year, from ($6.36) to ($8.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -31.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palvella Therapeutics is -31.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalvella Therapeutics has a P/B Ratio of 63.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Palvella Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.21% of the float of Palvella Therapeutics has been sold short.Short Interest Ratio / Days to CoverPalvella Therapeutics has a short interest ratio ("days to cover") of 11.14, which indicates bearish sentiment.Change versus previous monthShort interest in Palvella Therapeutics has recently increased by 6.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.24 News SentimentPalvella Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Palvella Therapeutics this week, compared to 6 articles on an average week.MarketBeat Follows4 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,526,138.00 in company stock.Percentage Held by Insiders17.20% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Stock News HeadlinesGeorge Jenkins Sells 12,371 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 17 at 4:22 AM | americanbankingnews.comGeorge Jenkins Sells 13,352 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 17 at 4:22 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Palvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 1,777 SharesSeptember 16 at 5:37 AM | insidertrades.comPalvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical OfficerSeptember 9, 2026 | finanznachrichten.dePalvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical OfficerSeptember 9, 2026 | finance.yahoo.comChristopher Kiritsy Sells 313 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 5, 2026 | insidertrades.comPalvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 SharesAugust 21, 2026 | insidertrades.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $104.67 at the beginning of 2026. Since then, PVLA shares have increased by 43.8% and is now trading at $150.56. How were Palvella Therapeutics' earnings last quarter? Palvella Therapeutics, Inc. (NASDAQ:PVLA) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $0.35. Read the conference call transcript. Who are Palvella Therapeutics' major shareholders? Palvella Therapeutics' top institutional shareholders include Montanova Capital LLC (7.88%), BlackRock Inc. (6.37%), First Light Asset Management LLC (5.36%) and Primecap Management Co. CA (1.78%). Insiders that own company stock include George M Jenkins, Elaine J Heron, Kathleen Goin and Christopher P Kiritsy. View institutional ownership trends. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/18/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PVLA's financial health is in the Green zone, according to TradeSmith. PVLA has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PVLA Previous SymbolNASDAQ:PVLA CIK1583648 Webwww.palvellatx.com Phone(484) 253-1461Fax49-8161-141-1444Employees29Year Founded2015Price Target and Rating Average Price Target for Palvella Therapeutics$209.14 High Price Target$270.00 Low Price Target$133.00 Potential Upside/Downside+38.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.84% Return on Assets-38.33% Debt Debt-to-Equity RatioN/A Current Ratio21.18 Quick Ratio21.18 Sales & Book Value Annual Sales$42.81 million Price / Sales50.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book63.80Miscellaneous Outstanding Shares14,410,000Free Float11,930,000Market Cap$2.17 billion OptionableN/A Beta-0.25 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PVLA) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVLA Stock Alerts